The city of São Paulo is located in the center of a metropolitan area with nearly 18 million inhabitants and 300,000 births/year. The currently existing medical genetics services are unable to meet the demand, due to their insufficient physical and personnel infrastructure. Institutions and experts in medical genetics could give short training and refresher courses to health professionals to enable them to work in the public health network. The city has a reasonably well developed health care network, represented by the Single Health System (Sistema Único de Saúde – SUS) and by the Family Health Program (Programa de Saúde da Família – PSF). The financial resources for such actions originate in the budget of the managing agencies of such systems. The limitations of genetic services provided to the population of the city could be overcome in a short period of time by developing programs within the public health care network. The city has institutions, professionals and financial resources to make this project feasible. To that end, the competent authorities of the São Paulo State and City Secretariats of Health should take managerial responsibility for the genetic services in the city.

Keywords:
Clinical genetics, Developing countries, Genetics services
1.
PAHO: Pan American Health Organization. Prevention and Control of Genetic Diseases and Congenital Defects. Report of an Advisory Group. Scientific Publication 1984;460. Washington, PAHO, 1984.
2.
Grupo de Trabalho: Conclusiones y recomendaciones de la reunión de expertos em servicios de genética médica em América Latina. Braz J Genet 1997;20(1 suppl):171–174.
3.
Penchaszadeh VB, Beiguelman B: Medical Genetics Services in Latin América. WHO publication WHO/HGN/CONS/MGS/98.4. Geneva, WHO, 1998.
4.
Penchaszadeh VB, Christianson AL, Giugliani R, Boulyjenkov V, Katz M: Services for the prevention and management of genetic disorders and birth defects in developing countries. Community Genet 1999;2:196–201.
5.
Penchaszadeh VB: Global Policy in Prevention of Genetic and Congenital Diseases. Recommendations for Genetic Services in Developing Countries. Conference Report World Alliance of Organizations for the Prevention of Birth Defects. Amsterdam, Ververs, 2000, pp 62–72.
6.
World Health Organization: Services for the Prevention and Management of Genetic Disorders and Birth Defects in Developing Countries. A Joint WHO/WAOPBD Meeting. The Hague, January 5–7, 1999. WHO/HGN/GL/WAOPBD 1999.
7.
Brunoni D: Estado atual do desenvolvimento dos serviços de genética médica no Brasil. Rev Bras Genet 1997;20(1 suppl):11–23.
8.
Brunoni D: O médico especialista em genética. Médicos 1999;II:49–53.
9.
Brunoni D: Aconselhamento Genético. Ciência & Saúde Coletiva 2002;7:101–107.
10.
Salzano FM: Saúde Pública no Primeiro e Terceiro Mundo: desafios e perspectivas. Ciência & Saúde Coletiva 2002;7:7–16.
11.
Marques-de-Faria AP, Ferraz VEF, Acosta AX, Brunoni D: Clinical genetics in developing countries: The case of Brazil. Community Genet 2004;7:95–105.
12.
IBGE: Instituto Brasileiro de Geografia e Estatística: Aspectos demográficos. Estatística de saúde 1999. Censo demográfico 2000. http://www.ibge.gov.br.
13.
MS: Ministério da Saúde da República Federativa do Brasil. http://www.saude.gov.br.
14.
DATASUS: Ministério da Saúde. Secretaria Executiva. http://www.datasus.gov.br/.
15.
Prefeitura do Município de São Paulo. http://www.prefeitura.sp.gov.br.
16.
FUNDAÇÃO SEADE: Fundação Sistema Estadual de Análise de Dados. Goverso do estado de São Paulo. Secretaria de estado de Economia e Planejamento. http://www.seade.gov.br.
17.
PSF: Programa Saúde da Família. Cidade de São Paulo. http://www5.prefeitura.sp.gov.br/.
18.
APAE-SP: Associação de Pais e Amigos dos Excepcionais de São Paulo. http://www.apaesp.org.br/index2.html.
19.
AACD: Associação de Assistência à Criança Defeituosa. http://www.aacd.org.br.
20.
Ramalho AS, de Paiva e Silva RB, Teixeira RC, Compri MB: Hemoglobin screening: Response of a Brazilian community to optional programs. Cadernos de Saúde Pública 1999;15:591–595.
21.
Ramalho AS, de Paiva e Silva RB: Community Genetics: A new discipline and its application in Brazil. Cadernos de Saúde Pública 2000;16:1.
22.
Decourt L, Sasso W, Chiorboli E, Caleiro M, Fernandes JM: Sobre o sexo genético nas pacientes com síndrome de Turner. Rev Ass Méd Bras 1954;1:203–206.
23.
Schmidt BJ, Martins AMM, Fisberg R, Adell ACA, Soares D, Müller R, Bechara J, Loghin-Grosso N, Diament AJ: Phenylketonuria (PKU): The Brazilian experience; in Schmidt BJ, Diament AJ, Loghin-Grosso NS (eds): Current Trends in Infant Screening. Amsterdam, Excerpta Medica, 1989, pp 65–70.
24.
Nazareth HRS, Pinto W, Andrade JAD: Diagnóstico pré-natal de aberrações cromossômicas: primeira experiência brasileira. Rev Bras Genet 1981;4:245–268.
25.
Gollop TR, Naccache NF, Campos I, Pieri P: Amostra de vilo-corial: 1290 casos. Rev Bras Ginecol 1993;15:84–87.
26.
FAPESP: Fundação de Assistência à Pesquisa do Estado de São Paulo. Relatório de Atividades 2001. http://www.fapesp.br.
27.
Brazilian National Genome Project Consortium: The genome sequence of the plant pathogen Xylella fastidiosa. The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequencing and Analysis. Nature 2000;406:151–157.
28.
Camargo AA, Samaia HP, Dias-Neto E, et al.: The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome. Proc Natl Acad Sci USA 2001 98:12103–12108.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.